Savara (SVRA) reported second quarter 2026 results showing a net loss of US$40.23 million and basic loss per share of US$0.16, alongside a US$108.297 million shelf registration filing.

Savara's recent earnings update and shelf registration come after a period where the share price has moved to US$5.59, with short term share price momentum supported by a 90 day share price return of 11.35%, alongside a 1 year total shareholder return of 76.9%.

If you are looking beyond Savara for other healthcare ideas, this is a good moment to see what else is moving in rare diseases and related areas using the 41 healthcare AI stocks

Bulls highlight Savara's rare disease focus and strong 1 year return. Bears point to ongoing losses and the new US$108.297 million shelf. Does the current valuation lean more toward optimism or caution?

Preferred Price-to-Book Multiple of 9.9x: Is It Justified for Savara?

At a last close of $5.59, Savara is trading on a P/B ratio of 9.9x, which is well above both the US Biotechs industry average of 2.5x and the peer average of 4.6x. That gap signals that the market is assigning a much richer valuation to Savara's equity than to many comparable biopharmaceutical companies.

The price to book ratio compares the market value of a company to its recorded net assets on the balance sheet. For early stage or clinical stage biopharmaceutical companies like Savara, P/B often reflects how investors view the potential of the pipeline and future earnings relative to the current asset base, since there is very limited current revenue.

With Savara generating less than US$1m in revenue and reporting losses, this elevated 9.9x P/B ratio suggests investors are paying a sizeable premium to the book value of the business. The premium could be linked to expectations around the rare respiratory disease focus and the Phase 3 molgramostim program. However, it also means the stock price is more sensitive to how those expectations evolve.

Compared with the broader US Biotechs industry P/B of 2.5x, Savara's 9.9x level is significantly higher. The ratio is also more than double the 4.6x peer average, which indicates the stock is valued much more aggressively than many similar sized biotech companies.

Result: Price-to-book of 9.9x (OVERVALUED)

However, Savara's ongoing net losses of US$139.309 million and the fresh US$108.297 million shelf could pressure sentiment if clinical or funding milestones disappoint.

Next Steps

Given the mix of optimism and concern around Savara right now, it helps to see the underlying data for yourself and decide where you stand. To weigh those potential upsides against the issues investors are watching, take a closer look at the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Savara?

If Savara has your attention, do not stop here. Use this moment to widen your watchlist and compare it with other focused opportunities across the market.

• Spot potential early movers by reviewing the 22 elite penny stocks with strong financials that meet stricter quality checks than many tiny stocks ever see.
• Sharpen your value hunting by scanning the 48 high quality undervalued stocks that combine stronger balance sheets with pricing that may not reflect their fundamentals.
• Strengthen the defensive side of your portfolio by checking out the 76 resilient stocks with low risk scores that carry more resilient risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.